A self-managed investor website and email program for a clinical-stage biotech

The challenge

With a steady flow of clinical and corporate news, the company needed to update its investor website quickly and email shareholders directly — but every website change meant a developer ticket or agency request, and investor emails were sent from a separate, disconnected tool.

The solution

We set the company up on ARC’s CMS and email tools. The IR team now publishes pages, updates and announcements to its investor site using on-brand templates and approval workflows, and sends investor newsletters and updates (EDM) to a managed subscriber list — all from one platform, no developer required.

What we developed

• ARC’s IR CMS for the investor website — no-code publishing with on-brand templates and approval workflows
• Investor email campaigns (EDM) — newsletters and corporate updates to a managed subscriber list, with open and click analytics
• Subscriber and contact-list management with built-in form capture
• Content workflows so the IR and comms team can publish and send without external help

The outcome

The company now manages its investor website and email program entirely in-house — publishing updates in minutes instead of waiting on a developer, and reaching shareholders directly. One platform replaced a separate website and email-tool setup, with clear visibility of what investors engage with.